Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Articles

Incidence and Risk Factors for Biliary Tract Cancers

September 21st 2022

Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.

An Overview on Biliary Tract Cancers

September 21st 2022

Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.

Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton

June 7th 2021

OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.

Dr. Javle on the FDA Approval of Infigratinib in FGFR-Mutated Cholangiocarcinoma

May 28th 2021

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

Perspectives on Treating CCA Moving Forward

May 3rd 2021

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

Immunotherapy for Advanced Cholangiocarcinoma

May 3rd 2021

The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.

Cholangiocarcinoma: Potential Therapies Under Investigation

April 26th 2021

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.

IDH Targeting in Advanced Cholangiocarcinoma

April 26th 2021

Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.

Implications for Using FGFR Inhibitors in Advanced CCA

April 19th 2021

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events

April 19th 2021

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

FGFR Inhibitors for Advanced Cholangiocarcinoma

April 12th 2021

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Promoting the Importance of Molecular Testing in CCA

April 12th 2021

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

Advanced Cholangiocarcinoma: Molecular Testing

April 5th 2021

Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.

Advanced Cholangiocarcinoma: Transition to Precision Medicine

April 5th 2021

A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.

Treating Unresectable, Advanced Cholangiocarcinoma

March 29th 2021

Treatment recommendations, including supportive care options and the role of liver-directed therapy for patients with an unresectable, advanced bile duct cancer.

Neoadjuvant Therapy for Advanced Cholangiocarcinoma

March 29th 2021

An overview of potential options, as well as trials, further exploring neoadjuvant approaches for the management of patients with advanced cholangiocarcinoma.

Optimizing Adjuvant Therapy for Advanced Cholangiocarcinoma

March 22nd 2021

Insight regarding best timing to initiate an appropriate adjuvant therapy in patients with advanced cholangiocarcinoma, and the role of ctDNA analysis in the postsurgical setting.

Adjuvant Therapy for Advanced Cholangiocarcinoma

March 22nd 2021

Current treatment approaches for advanced cholangiocarcinoma, despite current gaps that can be considered in the adjuvant setting, as highlighted by GI oncologists.

Liver Transplantation for Advanced Cholangiocarcinoma

March 15th 2021

Scenarios for which liver transplantation may be appropriate in advanced cholangiocarcinoma.

Advanced Cholangiocarcinoma: Criteria for Resection

March 15th 2021

Panelists discuss types of scans and other testing results that can be used to help identify patients with an advanced bile duct cancer who are eligible for surgical resection.